

Bethan Psaila

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1532507/publications.pdf>

Version: 2024-02-01

61
papers

6,055
citations

236925

25
h-index

189892

50
g-index

68
all docs

68
docs citations

68
times ranked

9228
citing authors

#	ARTICLE	IF	CITATIONS
1	Pre-metastatic niches: organ-specific homes for metastases. <i>Nature Reviews Cancer</i> , 2017, 17, 302-317.	28.4	1,272
2	The metastatic niche: adapting the foreign soil. <i>Nature Reviews Cancer</i> , 2009, 9, 285-293.	28.4	1,081
3	Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic Purpura. <i>New England Journal of Medicine</i> , 2007, 357, 2237-2247.	27.0	718
4	Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2009, 373, 641-648.	13.7	493
5	Bone marrow cells in the "pre-metastatic niche": within bone and beyond. <i>Cancer and Metastasis Reviews</i> , 2007, 25, 521-529.	5.9	282
6	Unravelling Intratumoral Heterogeneity through High-Sensitivity Single-Cell Mutational Analysis and Parallel RNA Sequencing. <i>Molecular Cell</i> , 2019, 73, 1292-1305.e8.	9.7	218
7	Niche-to-niche migration of bone-marrow-derived cells. <i>Trends in Molecular Medicine</i> , 2007, 13, 72-81.	6.7	204
8	Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases. <i>Blood</i> , 2009, 114, 4777-4783.	1.4	184
9	The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP. <i>British Journal of Haematology</i> , 2007, 138, 245-248.	2.5	140
10	Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia. <i>Blood</i> , 2011, 117, 5723-5732.	1.4	130
11	Single-cell profiling of human megakaryocyte-erythroid progenitors identifies distinct megakaryocyte and erythroid differentiation pathways. <i>Genome Biology</i> , 2016, 17, 83.	8.8	124
12	Single-Cell Analyses Reveal Megakaryocyte-Biased Hematopoiesis in Myelofibrosis and Identify Mutant Clone-Specific Targets. <i>Molecular Cell</i> , 2020, 78, 477-492.e8.	9.7	106
13	Priming the "Soil" for Breast Cancer Metastasis: The Pre-Metastatic Niche. <i>Breast Disease</i> , 2007, 26, 65-74.	0.8	103
14	Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator. <i>Blood</i> , 2017, 130, 1923-1933.	1.4	98
15	In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. <i>Blood</i> , 2012, 119, 4066-4072.	1.4	86
16	Refractory immune thrombocytopenic purpura: current strategies for investigation and management. <i>British Journal of Haematology</i> , 2008, 143, 16-26.	2.5	72
17	Immune Thrombocytopenic Purpura. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 743-759.	2.2	64
18	Regulation of Vasculogenesis by Platelet-Mediated Recruitment of Bone Marrow-Derived Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 217-222.	2.4	63

#	ARTICLE	IF	CITATIONS
19	Discovery of a CD10-negative B-progenitor in human fetal life identifies unique ontogeny-related developmental programs. <i>Blood</i> , 2019, 134, 1059-1071.	1.4	62
20	Artificial intelligence-based morphological fingerprinting of megakaryocytes: a new tool for assessing disease in MPN patients. <i>Blood Advances</i> , 2020, 4, 3284-3294.	5.2	51
21	Single-cell approaches reveal novel cellular pathways for megakaryocyte and erythroid differentiation. <i>Blood</i> , 2019, 133, 1427-1435.	1.4	47
22	Transitions in lineage specification and gene regulatory networks in hematopoietic stem/progenitor cells over human development. <i>Cell Reports</i> , 2021, 36, 109698.	6.4	38
23	Elucidation of the EP defect in Diamond-Blackfan anemia by characterization and prospective isolation of human EPs. <i>Blood</i> , 2015, 125, 2553-2557.	1.4	33
24	Single-cell profiling of human bone marrow progenitors reveals mechanisms of failing erythropoiesis in Diamond-Blackfan anemia. <i>Science Translational Medicine</i> , 2021, 13, eabf0113.	12.4	32
25	Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopenia. <i>American Journal of Hematology</i> , 2014, 89, E228-34.	4.1	31
26	Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms. <i>British Journal of Haematology</i> , 2021, 194, 1010-1015.	2.5	31
27	Fc receptors in immune thrombocytopenias: a target for immunomodulation?. <i>Journal of Clinical Investigation</i> , 2008, 118, 2677-81.	8.2	27
28	In utero origin of myelofibrosis presenting in adult monozygotic twins. <i>Nature Medicine</i> , 2022, 28, 1207-1211.	30.7	26
29	Stability of measurement of the immature platelet fraction. <i>American Journal of Hematology</i> , 2010, 85, 622-624.	4.1	24
30	Single-cell analysis of bone marrow-derived CD34+ cells from children with sickle cell disease and thalassemia. <i>Blood</i> , 2019, 134, 2111-2115.	1.4	21
31	HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progression. <i>Blood</i> , 2022, 139, 2797-2815.	1.4	20
32	CD34+CD19 ^{hi} CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies. <i>Blood</i> , 2022, 140, 38-44.	1.4	20
33	Novel Thrombopoietic Agents. <i>Hematology American Society of Hematology Education Program</i> , 2007, 2007, 106-113.	2.5	18
34	The BET inhibitor CPI203 promotes ex vivo expansion of cord blood long-term repopulating HSCs and megakaryocytes. <i>Blood</i> , 2020, 136, 2410-2415.	1.4	18
35	Enhanced engraftment of human myelofibrosis stem and progenitor cells in MISTRG mice. <i>Blood Advances</i> , 2020, 4, 2477-2488.	5.2	15
36	The immune landscape in BCR ⁺ CABL ⁻ negative myeloproliferative neoplasms: inflammation, infections and opportunities for immunotherapy. <i>British Journal of Haematology</i> , 2022, 196, 1149-1158.	2.5	11

#	ARTICLE	IF	CITATIONS
37	Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm. <i>Leukemia</i> , 2021, 35, 2424-2430.	7.2	8
38	Single-Cell Multi-Omics Reveals the Genetic, Cellular and Molecular Landscape of <i>TP53</i> Mutated Leukemic Transformation in MPN. <i>Blood</i> , 2021, 138, 3-3.	1.4	7
39	Immune Thrombocytopenia (ITP)., 2013, , 819-833.		6
40	Eltrombopag Mobilizes Intracellular Iron Stores at Concentrations Lower Than Those Required with Other Clinically Available Iron Chelators. <i>Blood</i> , 2014, 124, 1353-1353.	1.4	6
41	Interrogating the molecular genetics of chronic myeloproliferative malignancies for personalized management in 2021. <i>Haematologica</i> , 2021, 106, 1787-1793.	3.5	5
42	Application of Single-Cell Approaches to Study Myeloproliferative Neoplasm Biology. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 279-293.	2.2	5
43	Platelet Function and Response to Thrombopoietin Mimetics In Wiskott-Aldrich Syndrome/X-Linked Thrombocytopenia.. <i>Blood</i> , 2010, 116, 1429-1429.	1.4	5
44	Processing single-cell RNA-seq datasets using SingCellaR. <i>STAR Protocols</i> , 2022, 3, 101266.	1.2	5
45	Rapid Emergence of Chronic Lymphocytic Leukemia During JAK2 Inhibitor Therapy in a Patient With Myelofibrosis. <i>HemaSphere</i> , 2020, 4, e356.	2.7	4
46	Insights into Therapeutic Mechanisms: Measuring Immature Platelet Fraction (IPF) Describes Response to Treatment in Immune Thrombocytopenic Purpura (ITP).. <i>Blood</i> , 2006, 108, 1070-1070.	1.4	4
47	lluminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies. <i>Hematological Oncology</i> , 2020, 38, 654-664.	1.7	3
48	Comparison of Platelet Function and Bleeding in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura (ITP) and Chemotherapy-Induced Thrombocytopenia (CIT).. <i>Blood</i> , 2007, 110, 2094-2094.	1.4	3
49	Iron status influences the response of cord blood megakaryocyte progenitors to eltrombopag in <i>vitro</i> . <i>Blood Advances</i> , 2022, 6, 13-27.	5.2	2
50	IVIg in ITP: no role for cytokines?. <i>Blood</i> , 2007, 109, 4-5.	1.4	1
51	Tense your megas! Structural rigidity is key. <i>Blood</i> , 2016, 128, 1997-1999.	1.4	1
52	A tale of two alleles: <i>TP53</i> and transformation in MPNs. <i>Blood</i> , 2022, 139, 3567-3568.	1.4	1
53	B-cell depletion in immune thrombocytopenia. <i>Lancet, The</i> , 2015, 385, 1599-1601.	13.7	0
54	Sugar thieves and addicts: nutrient subversion in JAK2 MPNs. <i>Blood</i> , 2019, 134, 1778-1780.	1.4	0

#	ARTICLE	IF	CITATIONS
55	The Effect of Eltrombopag on Human Platelet Resistance to Apoptosis: The Role of the Bcl-XI Pathway. Blood, 2010, 116, 2520-2520.	1.4	0
56	Single Cell RNASeq Demonstrates That Mouse Erythroid Cells Are the Last Lineage to Emerge. Blood, 2018, 132, 1274-1274.	1.4	0
57	Molecular Characterisation of Participants in the Phazar Trial Reveals Prognostic Impact of Mutations in Advanced-Phase-MPN. Blood, 2020, 136, 40-41.	1.4	0
58	Single Cell Approaches to Elucidate Novel and Aberrant Pathways in Megakaryocytes. Blood, 2020, 136, SCI3-SCI3.	1.4	0
59	Modelling Myelofibrosis <i>in Vivo</i> : Success With NSG-S. , 2022, 19, .		0
60	Ultrastructural Changes in Platelets Portend Leukemogenesis. , 2022, 19, .		0
61	FEDORA: The Beginning of a Beautiful Friendship?. , 2022, 19, .		0